kras mutation and glutathion JCI Overcoming resistance to drugs targeting
Overcoming resistance to drugs targeting KRASG12C mutation Targeting KRAS Mutant Cancers with a Covalent G12C Specific Inhibitor: Cell KRAS targeted therapies in cancer: novel approaches and overcoming resistance BMJ Oncology Kinetic and Redox Characterization of KRAS G12C Inhibition bioRxiv Uncovering new therapeutic targets for a common KRAS mutation behind cancer
Pay in 4 interest-free payments of $7.10 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13




